Sourcing an ivd antibody for a diagnostic product: what separates a research reagent from one a manufacturer can build a device around, what to ask an antibody manufacturer about change control and lot reservation, and the documentation a supplier has to provide

What a diagnostic manufacturer has to establish

1. Establish the grade and what it commits the supplier to. Research use only material carries no commitment to consistency or notification. A reagent sold for diagnostic manufacture should come with a specification, a certificate per lot against it, and a stated change control process. Ask what the grade actually obliges the supplier to do.
2. Get change notification in the contract. A supplier changing a purification step, a host cell line or a buffer without telling you can invalidate a validated assay silently. Notification before change, with enough lead time to bridge, is the single most valuable term in the agreement.
3. Reserve a lot and bridge between lots. Reserve enough of one lot to cover production and validation, and run a bridging study when moving lots, comparing performance in the actual assay rather than on a binding measurement. Lot change is the commonest cause of a diagnostic assay drifting.
4. Collect the documentation your quality system needs. Specification, certificate of analysis per lot, animal origin and source material statements, a supplier quality agreement and audit rights. Supplier controls are a regulated requirement for a device manufacturer, not paperwork for its own sake.
5. Assess supply risk as seriously as performance. A single source reagent with no second supplier is a single point of failure for the product. Ask about capacity, about how long the supplier commits to producing it, and what notice of discontinuation you would receive.

Qualifying the reagent in your own assay

Performance in the device is the qualification that counts: sensitivity, specificity, the effect of the matrix and stability in the formulation. A supplier's binding data is an input and never a substitute.

Define acceptance criteria for an incoming lot in your own assay before the first lot change, so a bridging study has something to pass or fail rather than a judgement made under time pressure.

Second sourcing, and why it is hard here

A second antibody is a different molecule and qualifying it is a second validation, so a true second source is expensive. Many manufacturers instead secure supply by reserving inventory and by contractual commitments.

Where the volume justifies it, licensing the sequence and having the antibody produced recombinantly under your own control removes the single point of failure entirely. It is a larger project and it is the durable answer.

Animal origin and source material

Bovine and other animal derived components in the reagent or its formulation carry their own documentation requirements and can restrict markets. Ask for the statements at the point of selection rather than during a submission.

Where an animal free option exists at equivalent performance, it usually simplifies the regulatory path enough to be worth the switch, provided it is made before validation rather than after.

An alkaline phosphatase antibody, and the enzyme used as a label

Alkaline phosphatase appears twice in this field: as an analyte with tissue specific isoforms, and as the enzyme conjugated to a detection antibody. An alkaline phosphatase antibody detects the protein, which is a different purchase from an enzyme labelled secondary. Where the isoform is the question, the clone has to name it, since the placental, intestinal and bone forms are products of different genes.

An apob antibody and the two forms one gene makes

Editing produces a short intestinal form and a long hepatic form from the same transcript, so an apob antibody has to state which it detects and a blot shows a very large band that needs a low percentage gel. Clinical measurement is by immunoassay against calibrated standards rather than by blot, so a matched pair and a stated calibration are what a reported concentration rests on.

A lysozyme antibody and the tissues that express it

Lysozyme is abundant in Paneth cells, monocytes and secretions, which makes a lysozyme antibody a lineage marker in a section and an analyte in a fluid. The protein is small and cationic, so it transfers quickly and can pass through a membrane during a long transfer. A shorter transfer and a smaller pore membrane are the practical answers when the band is faint.

A 21 hydroxylase antibody and the autoantibody it is used to detect

This antigen matters mostly as the target of patient autoantibodies in adrenal insufficiency, so the usual purchase is the antigen or an assay rather than a detection antibody. A 21 hydroxylase antibody in the catalogue sense detects the enzyme in a section or a blot, and the enzyme is a microsomal cytochrome P450, so a membrane preparation rather than a cytosolic lysate is where it is found.

A tissue factor antibody and the difference between antigen and activity

Tissue factor is measured as protein and as procoagulant activity, and the two do not track each other, because the protein can be present in an inactive configuration. A tissue factor antibody reports antigen; a clotting assay reports activity. For a blocking experiment the clone has to be stated as inhibitory, which is a separate validation from detection on a blot.

A hemoglobin antibody and a myoglobin antibody in the same sample

These two globins overlap in size and in the reason they are measured, so cross reactivity is the first thing to check: a hemoglobin antibody used on a muscle sample and a myoglobin antibody used on a blood contaminated one both risk reading the other protein. Both are abundant, so dilution rather than sensitivity is the problem, and a dilution series is what shows the reading is in range.

A ceruloplasmin antibody and the copper it carries

Ceruloplasmin is a plasma protein whose concentration is read in copper disorders and as an acute phase reactant, so a ceruloplasmin antibody is usually part of an immunoassay rather than a blot. The apo form and the holo form differ in stability, and the protein is cleaved by proteases in stored plasma, so sample age and handling change the answer more than the clone does.

Common questions

What makes an ivd antibody different from a research antibody?

Commitments rather than chemistry: a written specification, a certificate per lot, change notification, lot reservation and documentation your quality system can use. The same clone can be sold at both grades with very different obligations attached.

Can I use a research use only antibody in a diagnostic product?

The labelling restricts the supplier's claim, and the obligation to qualify what goes into a device is the manufacturer's. In practice a reagent with no specification, no change control and no lot certificate is very difficult to qualify and to keep qualified.

Why is change notification so important?

Because an undisclosed process change can shift assay performance without anything visibly failing. Notification with lead time is what lets you bridge lots deliberately instead of discovering a shift in production.

What documentation should a supplier provide?

A product specification, a certificate of analysis per lot against it, source and animal origin statements, and a quality agreement covering change notification and audit rights. Ask for a sample set before committing.

Browse by service class

• Compare Gene synthesis on advertised prices